1 day Ago By Defense World Staff
Equities researchers at StockNews.com started coverage on shares of Genocea Biosciences ( NASDAQ:GNCA – Get Free Report ) in a research note issued on Monday. The brokerage set a “sell” rating on the biotechnology company’s stock.
Genocea Biosciences Stock Performance The company has a market capitalization of $6,000.00, a PE ratio of 0.00 and a beta of 1.
61. Genocea Biosciences has a 52 week low of $0.00 and a 52 week high of $0.
00. The company has a debt-to-equity ratio of 0.24, a current ratio of 1.
35 and a quick ratio of 1.35. Genocea Biosciences Company Profile ( Get Free Report ) Featured Stories Five stocks we like better than Genocea Biosciences What Are Growth Stocks and Investing in Them Super Micro Computer Soars 28%: Is It Really Out of the Woods? Bank Stocks – Best Bank Stocks to Invest In Traders Are Flocking Back to Oil: What’s Fueling the Optimism The 3 Best Retail Stocks to Shop for in August 3 Hot Stock Trends to Ride Into 2025 Receive News & Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related companies with MarketBeat.
com's FREE daily email newsletter ..
